title: [Kidney transplantation using living donors over age 65].
abstract: Efforts to increase the donor pool of available organs have resulted in some unconventional kidney transplantation procedures. One of these is the use of elderly donors for both living and cadaver kidney transplantations. The aim of this study was to review our experience with kidney transplants from living elderly donors. During a period of 10 years, 70 living renal transplantations were performed. In 32 transplants the age of the donor was above 65 years (mean 69 +/- 4 years, range: 65 to 81 years) and in 10 of these 32 transplants the age of the donor was over 70 years. The survival rate was compared with that of 38 transplants from younger donors (mean age 51 +/- 6 years, range: 24 to 59 years). The time to cold and warm ischemia, the preservation procedure and time to anastomosis of blood vessels were comparable in both groups of donors. Immunosuppression included a sequential quadruple protocol, using thymoglobulin (ATG), prednisolone (PRED), azathioprin (AZA) and cyclosporin A (CsA), which replaced ATG/PRED after day seven. A triple drug maintenance therapy (AZA, PRED, CsA) was used in all recipients. Kaplan-Meier survival curves at 1, 3 and 5 years showed that graft survival was 88%, 79% and 64% respectively for grafts from the advanced age donor group and 92%, 82% and 68% respectively for grafts from the younger donor group. The difference was slightly statistically significant (p < 0.05). Functioning of the graft was delayed in six patients who had received grafts from elderly donors and in one patient who had received a graft from a young donor. Despite worse results in transplantation with grafts from elderly donors, we consider this population as an important source of kidneys, which might help solve the present organ shortage, especially in our region.
authors.affiliation: Centre hospitalier universitaire Skopje, clinique de néphrologie, unité de transplantation, Skopje, République de Macédoine.
authors.forename: N
authors.initials: N
authors.lastname: Ivanovski
authors.forename: Z
authors.initials: Z
authors.lastname: Popov
authors.forename: P
authors.initials: P
authors.lastname: Kolevski
authors.forename: K
authors.initials: K
authors.lastname: Cakalaroski
authors.forename: G
authors.initials: G
authors.lastname: Spasovski
authors.forename: O
authors.initials: O
authors.lastname: Stankov
authors.forename: O
authors.initials: O
authors.lastname: Stojceva-Taneva
authors.forename: J
authors.initials: J
authors.lastname: Paneva-Masin
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007511:Ischemia; D016030:Kidney Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000628:therapy; D012189:Retrospective Studies; D016019:Survival Analysis; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents